ImmunoCellular Therapeutics (IMUCD) Short Interest Ratio & Short Volume → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free IMUCD Stock Alerts $0.18 -0.05 (-21.46%) (As of 03/27/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartStock AnalysisChart ImmunoCellular Therapeutics Short Interest DataCurrent Short Volume100 sharesPrevious Short Volume1,200 sharesChange Vs. Previous Month-91.67%Dollar Volume Sold Short$0.00Short Interest Ratio / Days to Cover0.0Last Record DateSeptember 30, 2020Outstanding Shares4,190,000 sharesPercentage of Shares Shorted0.00%Today's Trading Volume38,119 sharesAverage Trading Volume6,605 sharesToday's Volume Vs. Average577% Short Selling ImmunoCellular Therapeutics ? Sign up to receive the latest short interest report for ImmunoCellular Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatIMUCD Short Interest Over TimeIMUCD Days to Cover Over TimeIMUCD Percentage of Float Shorted Over Time Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one ImmunoCellular Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/30/2020100 shares $0.00 -91.7%N/A0 $0.00 IMUCD Short Interest - Frequently Asked Questions What is ImmunoCellular Therapeutics' current short interest? Short interest is the volume of ImmunoCellular Therapeutics shares that have been sold short but have not yet been closed out or covered. As of September 30th, traders have sold 100 shares of IMUCD short. Learn More on ImmunoCellular Therapeutics' current short interest. Is ImmunoCellular Therapeutics' short interest increasing or decreasing? ImmunoCellular Therapeutics saw a decrease in short interest during the month of September. As of September 30th, there was short interest totaling 100 shares, a decrease of 91.7% from the previous total of 1,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does ImmunoCellular Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to ImmunoCellular Therapeutics: Neptune Wellness Solutions Inc (0.54%), Cingulate Inc. (0.29%), Evelo Biosciences, Inc. (2.11%), Aditxt, Inc. (1.79%), China SXT Pharmaceuticals, Inc. (1.00%), RespireRx Pharmaceuticals Inc. (0.01%), SciSparc Ltd. (5.67%), Baudax Bio, Inc. (1.11%), Tenax Therapeutics, Inc. (2.17%), Bellerophon Therapeutics, Inc. (0.55%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.91 billion), Aon plc ($3.68 billion), The Clorox Company ($2.92 billion), Analog Devices, Inc. ($2.35 billion), Uber Technologies, Inc. ($2.27 billion), Moderna, Inc. ($2.14 billion), The Kroger Co. ($2.14 billion), Datadog, Inc. ($2.00 billion), Simon Property Group, Inc. ($1.85 billion), and International Flavors & Fragrances Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short ImmunoCellular Therapeutics stock? Short selling IMUCD is an investing strategy that aims to generate trading profit from ImmunoCellular Therapeutics as its price is falling. IMUCD shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ImmunoCellular Therapeutics? A short squeeze for ImmunoCellular Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IMUCD, which in turn drives the price of the stock up even further. How often is ImmunoCellular Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMUCD, twice per month. The most recent reporting period available is September, 30 2020. More Short Interest Resources from MarketBeat Related Companies: Neptune Wellness Solutions Short Interest Data Cingulate Short Interest Data Evelo Biosciences Short Interest Data Aditxt Short Interest Data China SXT Pharmaceuticals Short Interest Data RespireRx Pharmaceuticals Short Interest Data SciSparc Short Interest Data Baudax Bio Short Interest Data Tenax Therapeutics Short Interest Data Bellerophon Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:IMUCD) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research